A case of longitudinal care of a patient with cardiac sarcoidosis
Cardiac sarcoidosis has long been an evasive diagnosis with a spectrum of clinical presentations that extend from asymptomatic to ventricular arrhythmias and sudden cardiac death. The diagnosis has traditionally relied on histology which suffers from the low sensitivity of endomyocardial biopsy due to the patchy nature of the disease in addition to its invasive nature. Due to significant advancements in imaging, it is now possible to accurately identify cardiac sarcoidosis using non-invasive imaging modalities even without histological confirmation. Emerging guidelines are highlighting the role of multimodality imaging in the diagnosis and management of this challenging entity. We present the case of a 36-year-old man known to have sarcoidosis in which a variety of imaging modalities not only assisted in the diagnosis of cardiac sarcoidosis, but also played a key role in the monitoring of disease activity and response to therapy.
KeywordsPET/CT imaging Magnetic resonance imaging Radiopharmaceuticals Inflammation Diagnostic and prognostic applications
Single-photon emission tomography
Myocardial perfusion imaging
Positron emission tomography
Cardiac magnetic resonance imaging
Late gadolinium enhancement
Cardiac computer tomography angiography
Dr. Hage has received research grant support from Astellas Pharma. Drs. Bhambhvani, Iskandrian and Saab have no conflicts.
- 7.Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 1015;2013(29):e1–3.Google Scholar
- 14.Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914–31.CrossRefPubMedGoogle Scholar
- 21.Slart R, Glaudemans A, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and inflammation & infection committees of the european association of nuclear medicine, the European association of cardiovascular imaging, and the American Society of nuclear cardiology. J Nucl Cardiol. 2017;8(10):1073–89. https://doi.org/10.1093/ehjci/jex146.Google Scholar
- 38.Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in (1)(8)F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74.CrossRefPubMedGoogle Scholar
- 44.Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9:e005001.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Greulich S, Kitterer D, Latus J, Aguor E, Steubing H, Kaesemann P, et al. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging. 2016;9:PMID: 27903537.Google Scholar